"Hormesis" - An inappropriate extrapolation from the specific to the universal

International Journal of Occupational and Environmental Health

Volumn 10, Issue 3, 2004, Pages 335-339

  Axelrod, Deborah ^a   Burns, Kathy ^b   Davis, Devra ^c   Von Larebeke, Nicolas ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b ABT ASSOCIATES   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hormesis; Risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; CHEMICAL AGENT; TAMOXIFEN; THALIDOMIDE;

ASTHMA; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; ENDOMETRIUM HYPERPLASIA; EXPOSURE; GASTROINTESTINAL HEMORRHAGE; HORMESIS; HUMAN; POLICY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; TERATOGENICITY; UTERUS CANCER; UTERUS SARCOMA;

EID: 4444378251     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/oeh.2004.10.3.335     Document Type: Review

References (45)

1. Renner R. Redrawing the dose-response curve. Environ Sci Technol. 2004;38(5):90A-95A.
2. Calabrese EJ, Baldwin LA. Toxicology rethinks its central belief. Nature. 2003:421:691-2.
3. Kaiser J. Hormesis. Sipping from a poisoned chalice. Science. 2003:302:376-9.
4. Kaiser J. Hormesis. A healthful dab of radiation? Science. 2003; 302:78.
5. Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect. 2003;111:994-1006.
6. Calabrese EJ, Baldwin LA. Defining hormesis. Hum Exp Toxicol. 2002;21:91-7.
7. Calabrese EJ. Expanding the RfD concept to incorporate and optimize beneficial effects while preventing toxic responses from non-essential toxicants. BELLE Newsletter. 1995:4.
8. Calabrese EJ, Baldwin LA. Hormesis: the dose-response revolution. Annu Rev Pharmacol Toxicol. 2003;43:175-97.
9. Juni RL, McElveen JC Jr. Environmental law applications of hormesis concepts: risk assessment and cost-benefit implications. J Appl Toxicol. 2000:20:149-55.
10. Kociba RJ, Keyes DG, Beyer JE, et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol. 1978; 46:279-303.
11. Rier SE, Martin DC, Bowman RE, Domowski WP, Becker JL. Endometriosis in rhesus monkeys (Macaca mulatto) following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam Appl Toxicol. 1993;21:433-41.
12. Schwartz GG, Il'yasova D, Ivanova A. Urinary cadmium impaired fasting glucose, and diabetes in the NHANES III. Diabetes Care. 2003;26:468-70.
13. Kanter M, Yoruk M, Koc A, Meral I, Karaca T. Effects of cadmium exposure on morphological aspects of pancreas, weight; of fetus and placenta in streptozotocin-induced diabetic pregnant rats. Biol Trace Elem Res. 2003;93:189-200.
14. Han JC, Park SY, Hah BG, et al. Cadmium induces impaired glucose tolerance in rat by down-regulating GLUT4 expression in adipocytes. Arch Biochem Biophys. 2003;413:213-20.
15. Merali Z, Singhal RL. Diabetogenic effects of chronic oral cadmium adminstration to neonatal rats. Br J Pharmacol. 1980 69:151-7.
16. Coyer R. Toxic effects of metals. In: Amdur M, Doull J, Klaassen C (eds). Casarett and Doull's Toxicology, The Basic Science of Poisons. 4th ed. New York: McGraw-Hill, Inc, 1991.
17. Sood B, Delaney-Black V, Covington C, et al. Prenatal alcohol exposure and childhood behavior at age 6 to 7 years: I. Dose-response effect. Pediatrics. 2001;108:E34.
18. Sokol RJ, Delaney-Black V, Nordstrom B. Fetal alcohol spectrum disorder. JAMA. 2003;290:2996-9.
19. Smith-Warner SA, Spiegelman D, Yaun S-S, et al. Alcohol and breast cancer in women: A pooled analysis of cohort studies JAMA. 1998;279:535-40.
20. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for lead: Health effects chapter. 1999.
21. National Research Council (NRC). Toxicological Effects of Methylmercury. Washington, DC: National Academy Press 2000.
22. Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002; 66:185-200.
23. Hattis D, Ginsberg G, Sonawane B, et al. Differences in pharm macokinetics between children and adults - II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal. 2003;23:117-42.
24. Hulla JE, Miller MS, Taylor JA, et al. Symposium overview: the role of genetic polymorphism and repair deficiencies in environmental disease. Toxicol Sci. 1999;47:135-43.
25. Ecobichon DJ, Stephens DS. Perinatal development of human blood esterases. Clin Pharmacol Then 1973;14:41-7.
26. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect. 2003;111:1403-9.
27. Wang X, Huang J, Fan Z, et al. Genetic and environmental factors associated with plasma paraoxonase activity in healthy Chinese. Int J Mol Med. 2004;13:445-50.
28. Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol. 2003;63:945-56.
29. Sams C, Mason HJ. Detoxification of organophosphates by Aesterases in human serum. Hum Exp Toxicol. 1999;18:653-8.
30. Ginsberg G, Smolenski S, Hattis D, Sonawane B. Population distribution of aldehyde dehydrogenase-2 genetic polymorphism: implications for risk assessment. Regul Toxicol Pharmacol. 2002;36:297-309.
31. Centers for Disease Control and Prevention (CDC). Second National Report on Human Exposure to Environmental Chemicals (released January 31, 2003).
32. Environmental Working Group (EWG). Body Burden: The Pollution in People. 2003.
33. Schecter A, Pavuk M, Papke O, Ryan JJ, Birnbaum L, Rosen R. Polybrominated diphenyl ethers (PBDEs) in U.S. mothers' milk. Environ Health Perspect. 2003;111:1723-9.
34. 3M. Analysis of pooled human sera and plasma and monkey sera for fluorocarbons using exygen method ExM-023-071. Report prepared for 3M, St. Paul, MN, by Exygen Research, State College, PA. Sponsor study number E02-1071; Exygen Study Number: 023-082 EPA docket AR226-1152. 2002.
35. Olsen GW, Burris JM, Lundberg JK, Hansen KJ, Mandel JH, Zobel LR. Final report: Identification of fluorochemicals in human sera. III. Pediatric participants in a group A streptococci clinical trial investigation. Study conducted by Corporate Occupational Medicine, Medical Department, 3M Company. EPA Docket AR226-1085. 2002.
36. Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusco TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 pg per deciliter. N Engl J Med. 2003;348:1517-26,
37. Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol. 2003;42:809-15.
38. Werner M, Kelsberg G, Weismantel AM, Aitken PV. Which healthy adults should take aspirin? J Fain Pract. 2004;53:146-50.
39. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328:434.
40. Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reyes' syndrome warning. Final rule. Fed Reg. 2003;68:13861-9.
41. Jacobson JM, et al. Thalidomide for the treatment of oral aphthous ulcer in patient with HIV infection. N Engl J Med. 1997;337:1086-7.
42. Krimskey S. Science in the Private Interest. New York: Rowman and Littlefield, 2003.
43. National Toxicology Program (NTP). The 9th Report on Carcinogens (ROC) Listing of Tamoxifen as a Known Human Carcinogen: Fact Sheet. 2000.
44. Harvey PW, Darbre P. Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women? J Appl Toxicol. 2004;24:167-76.
45. Texas Institute for Advancement of Chemical Technology (TIACT). Chemical hormesis: beneficial effects at low exposures, adverse effects at high exposures. College Station, TX, 1998.